title: The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model.
abstract: Photodynamic therapy was studied in dogs with and without posterior fossa glioblastomas. This mode of therapy consisted of intravenous administration of Photofrin-II at doses ranging from 0.75 to 4 mg/kg 24 hours prior to laser light irradiation in the posterior fossa. Tissue levels of Photofrin-II were four times greater in the tumor than in the surrounding normal brain. Irradiation was performed using 1 hour of 500 mW laser light at a wavelength of 630 nm delivered through a fiberoptic catheter directly into the tumor bed via a burr hole. All animals receiving a high dose (4 or 2 mg/kg) of Photofrin-II developed serious brain-stem neurotoxicity resulting in death or significant residual neurological deficits. A lower dose (0.75 mg/kg) of Photofrin-II produced tumor kill without significant permanent brain-stem toxicity in either the control animals or the animals with cerebellar brain tumors receiving photodynamic therapy.
authors.affiliation: Department of Neurology, Medical College of Wisconsin, MACC Fund Research Center, Milwaukee.
authors.forename: H T
authors.initials: HT
authors.lastname: Whelan
authors.forename: M H
authors.initials: MH
authors.lastname: Schmidt
authors.forename: A D
authors.initials: AD
authors.lastname: Segura
authors.forename: T L
authors.initials: TL
authors.lastname: McAuliffe
authors.forename: D M
authors.initials: DM
authors.lastname: Bajic
authors.forename: K J
authors.initials: KJ
authors.lastname: Murray
authors.forename: J E
authors.initials: JE
authors.lastname: Moulder
authors.forename: D R
authors.initials: DR
authors.lastname: Strother
authors.forename: J P
authors.initials: JP
authors.lastname: Thomas
authors.forename: G A
authors.initials: GA
authors.lastname: Meyer
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003388:Cranial Fossa, Posterior; D017323:Dihematoporphyrin Ether / Q000493:pharmacokinetics / Q000627:therapeutic use; D004285:Dogs; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008279:Magnetic Resonance Imaging; D010778:Photochemotherapy; D012016:Reference Values
chemical_list: D017323:Dihematoporphyrin Ether